Vincristine Injection Franchise in Ahmedabad

Anticancer Injection Supplier in Mumbai

Oncology Injection Distributor in Delhi

Hospital PCD Pharma Franchise in Bangalore

Vincristine Injection Stockist in Hyderabad
Oncology Injection Manufacturer & Exporter in Chandigarh

Home/Products /vincristine-1mg-injection

Vincept 1 Injection

Composition : Vincristine (1mg) Injection

Dosage Form : Injection

Packaging Type : Vial

Packaging : 1mg

Price : ₹1/-

Vincept 1 Injection contains Vincristine 1mg, a vinca alkaloid chemotherapeutic agent used for the treatment of various cancers including acute leukemia, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, and certain solid tumors. It is administered under strict medical supervision in hospital and oncology care settings.

Vincristine works by inhibiting microtubule formation in cancer cells, preventing cell division and inducing apoptosis. This targeted mechanism helps control the rapid proliferation of malignant cells effectively.

This injection is commonly used as part of combination chemotherapy regimens, allowing oncologists to adjust dosage according to patient-specific treatment protocols. Its intravenous formulation ensures precise delivery and optimal therapeutic efficacy.

Vincept 1 Injection is valued for its clinical reliability and consistent hospital demand, making it an essential product in oncology treatment portfolios. Its role in managing serious cancers supports improved patient outcomes and adherence to established chemotherapy protocols.

Read More

About the Product

Vincept 1 Injection contains Vincristine 1mg, a vinca alkaloid chemotherapeutic agent used for the treatment of various cancers including acute leukemia, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, and certain solid tumors. It is administered under strict medical supervision in hospital and oncology care settings.

Vincristine works by inhibiting microtubule formation in cancer cells, preventing cell division and inducing apoptosis. This targeted mechanism helps control the rapid proliferation of malignant cells effectively.

This injection is commonly used as part of combination chemotherapy regimens, allowing oncologists to adjust dosage according to patient-specific treatment protocols. Its intravenous formulation ensures precise delivery and optimal therapeutic efficacy.

Vincept 1 Injection is valued for its clinical reliability and consistent hospital demand, making it an essential product in oncology treatment portfolios. Its role in managing serious cancers supports improved patient outcomes and adherence to established chemotherapy protocols.

Common side effects may include constipation, nausea, vomiting, hair loss, and fatigue. Serious side effects may include peripheral neuropathy, muscle weakness, abdominal pain, bone marrow suppression, and increased risk of infections. Patients should be closely monitored throughout therapy.

Vincept 1 Injection is indicated for the treatment of acute lymphoblastic leukemia, Hodgkin’s and non-Hodgkin’s lymphoma, Wilms’ tumor, neuroblastoma, and other malignancies as prescribed by an oncologist. It is commonly used in multi-drug chemotherapy protocols.

Vincept 1 Injection must be administered only by trained healthcare professionals in a specialized hospital or oncology setting. Intrathecal administration is strictly contraindicated and can be fatal. Dosage must be carefully calculated, and patients should immediately report neurological symptoms or severe constipation.

Store Vincept 1 Injection in a cool, dry place away from direct sunlight. Keep the vial tightly closed and out of reach of children. Do not use if the solution appears discolored or contains particulate matter.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation